Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.37 |
| ▸ | AR | P10275 | 9/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958052 | 0.83 | KIF11 (0.44) | KIF11 | |
| SCHEMBL8330048 | 0.79 | MPL (0.37) | MPLARSLC22A12KMOPTPN7 | |
| SCHEMBL10232830 | 0.78 | NOTUM (0.39) | — | |
| SCHEMBL29954400 | 0.78 | HTR3E (0.47) | — | |
| SCHEMBL30642407 | 0.78 | HTR3E (0.47) | — | |
| SCHEMBL10232891 | 0.78 | ALKBH5 (0.37) | AR | |
| SCHEMBL2922332 | 0.75 | CES2 (0.36) | — | |
| SCHEMBL29952900 | 0.73 | HTR3E (0.36) | KMOGRM4 | |
| SCHEMBL10232931 | 0.73 | NOTUM (0.40) | — | |
| SCHEMBL12303902 | 0.73 | NOTUM (0.40) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9611222-B2 | Pyridine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | MPL 121/4885AR 2563/4885SLC22A12 3684/4885 |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, CACNA1A, KCNA1 | MPL 3823/4885AR 1251/4885SLC22A12 1180/4885 |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | MPL 3605/4885AR 2792/4885SLC22A12 1753/4885 |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | TRPV1, CACNA1A, KCNA1 | MPL 3823/4885AR 1251/4885SLC22A12 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.